HC Wainwright Issues Pessimistic Estimate for CRVS Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Investment analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 11th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of ($0.86) for the year, down from their previous estimate of ($0.83). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.26) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($0.43) EPS and FY2030 earnings at $0.45 EPS.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, September 16th. Wall Street Zen cut shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Ladenburg Thalmann & Co. Inc. upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Monday, October 26th. Finally, Mizuho set a $27.00 price objective on shares of Corvus Pharmaceuticals in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $32.83.

Corvus Pharmaceuticals Stock Down 7.4%

NASDAQ:CRVS opened at $10.62 on Friday. The stock’s 50-day simple moving average is $11.26 and its 200 day simple moving average is $14.10. The firm has a market capitalization of $895.80 million, a PE ratio of -14.96 and a beta of 1.57. Corvus Pharmaceuticals has a twelve month low of $6.39 and a twelve month high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Global Retirement Partners LLC bought a new position in shares of Corvus Pharmaceuticals during the second quarter valued at $30,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Corvus Pharmaceuticals in the second quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Corvus Pharmaceuticals during the 3rd quarter worth $50,000. State of Wyoming bought a new position in Corvus Pharmaceuticals during the 2nd quarter worth $71,000. Finally, Meeder Asset Management Inc. acquired a new position in Corvus Pharmaceuticals during the 2nd quarter worth about $90,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Key Stories Impacting Corvus Pharmaceuticals

Here are a few of the latest stories about CRVS:

• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple periods, including FY2026 to a loss of $0.86 per share from $0.83, FY2027 to a loss of $1.04 from $0.80, and FY2028 to a loss of $0.90 from $0.37. Estimates for several 2027 quarters were also cut. Its FY2030 forecast still implies a profit, but was reduced to $0.45 per share from $0.67. The broad revisions point to weaker expected earnings and a longer path to profitability. Corvus Pharmaceuticals analyst estimates

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.